Trends in mortality in people with HIV from 1999 through 2020: a multicohort collaboration

Tusch, E.; Ryom, L.; Pelchen-Matthews, A.; Mocroft, A.; Elbirt, D.; Oprea, C.; ... ; RESPOND Cohort Study (2024)

Article / Letter to editor

Background

Mortality among people with human immunodeficiency virus (HIV) declined with the introduction of combination antiretroviral therapy. We investigated trends in mortality in people with HIV from 1999 through 2020.

Methods

Data were collected from the Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) cohort between January 1999 through January 2015 and the International Cohort Consortium of Infectious Disease (RESPOND) from October 2017 through December 2020. Age-standardized all-cause and cause-specific mortality rates, classified using Coding Causes of Death in HIV, were calculated. Poisson models were used to assess mortality over time.

Results

Among 55 716 participants followed for median 6 years (interquartile range, 3–11), 5263 died (mortality rate [MR], 13.7/1000 person-years of follow-up [PYFU]; 95% confidence interval [CI], 13.4–14.1). Changing mortality was observed: AIDS mortality was most common between 1999–2009 (n = 952; MR, 4.2/1000 PYFU; 95% CI, 4.0–4.5) and non-AIDS–defining malignancy (NADM) between 2010–2020 (n = 444; MR, 2.8/1000 PYFU; 95% CI, 2.5–3.1). In multivariable analysis, all-cause mortality declined (adjusted mortality rate ratio [aMRR], 0.97 per year; 95% CI, .96–.98), mostly 1999–2010 (aMRR, 0.96 per year; 95% CI, .95–.97) but was stable 2011–2020 (aMRR, 1.00 per year; 95% CI, .96–1.05). Mortality due to all known causes except NADM also declined.

Conclusions

Mortality among people with HIV in the D:A:D and/or RESPOND cohorts declined between 1999–2009 and was stable over the period 2010–2020. This decline in mortality was not fully explained by improvements in immunologic–virologic status or other risk factors.

• mortality
• people with HIV
• HIV
• observational cohort
• cohort collaboration

• All authors: Tusch, E.; Ryom, L.; Pelchen-Matthews, A.; Mocroft, A.; Elbirt, D.; Oprea, C.; Günthard, H.F.; Staehelin, C.; Zangerle, R.; Suarez, I.; Vehreschild, J.J.; Wit, F.; Menozzi, M.; Monforte, A.D.; Spagnuolo, V.; Pradier, C.; Carlander, C.; Suanzes, P.; Wasmuth, J.C.; Carr, A.; Petoumenos, K.; Borgans, F.; Bonnet, F.; Wit, S. de; El-Sadr, W.; Neesgaard, B.; Jaschinski, N.; Greenberg, L.; Hosein, S.R.; Gallant, J.; Vannappagari, V.; Young, L.; Sabin, C.; Lundgren, J.; Peters, L.; Reekie, J.; DAD Cohort Study; RESPOND Cohort Study
• Date: 2024-04-26
• Journal: Clinical Infectious Diseases
• Volume: 79
• Issue: 5
• Pages: 1242 - 1257
• DOI: doi:10.1093/cid/ciae228
• Link: https://academic.oup.com/cid/article/79/5/1242/7658417